ImageneBio Inc (IMA) Stock AnalysisIMAImageneBio Inc

ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. It operates in the Healthcare sector.

ImageneBio Inc is not a strong buy right now due to its current price of $5.34, which is significantly below the analyst price target of $28. However, the stock has an RSI of 29.5, indicating it is oversold, which could suggest a potential rebound. The main risk is the significant net loss of $10.6 million reported in Q1 2026, which raises concerns about the company's financial health.